Dr. Buelow has worked in biotechnology for over twenty years and has extensive pharmaceutical experience. Dr. Buelow is a founder of OMT (2007), a fully human monoclonal antibody platform based on transgenic rats, and THP, Inc. (2003), a biotechnology company that engineered rabbits to produce human antibodies and was acquired by Roche in March 2007. Between 1993 and 2003, Dr. Buelow was senior vice president of Research and Development at SangStat Medical Corporation, where he developed RDP58, an anti-inflammatory compound that demonstrated efficacy in a placebo-controlled, blinded Phase II study in ulcerative colitis patients. Dr. Buelow has published more than 100 manuscripts and is an inventor on more than 25 patents.
Jeff Bird focuses on healthcare, including biotechnology and medical devices. Recent Series A investments include Forty Seven Inc. (monoclonal antibody immuno-oncology therapies) and XIOS Therapeutics (small molecular immuno-oncology.) In the genomics space, Jeff is a co-investor with Illumina in Helix (consumer genomics marketplace) and GRAIL (cancer screening test). Jeff was CEO and an investor at Verinata Health (noninvasive prenatal diagnosis). After their acquisition by Illumina in early 2013, he served as their GM for a year. He is currently a board member at NuGen Technologies(research reagents), Portola Pharmaceuticals (PTLA,a spin-out of Cor/Millennium focused on cardiovascular therapeutics), Restoration Robotics (aesthetic surgery devices), and Teneobio (next generation antibodies). He also represents the firm’s investments in Acceleron Pharmaceuticals (XLRN, metabolic therapeutics) and Pacific Biosciences (PACB, DNA sequencing). Jeff was formerly a director at Horizon Pharma (HZNP), Akarx Inc., (acquired by MGI Pharma in 2008), BARRX Medical, Inc. (acquired by Covidien in 2012) and Idun Pharmaceuticals, (acquired by Pfizer in 2005). Jeff was previously Senior Vice President, Business Operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He was primarily responsible for several alliances with major pharmaceutical companies and helped Gilead to acquire NeXstar in a $550 million transaction. His commercial responsibilities included direct sales in the US and Europe. Jeff received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School.
Rick is a seasoned entrepreneur with over three decades of successful executive management experience. He currently serves as consultant, advisor and director to Teneobio, Inc. a next generation biotechnology company. He has served as a Director for a number of Life Science companies. He served as Chairman, President and CEO and Director of SangStat Medical, a publicly traded, fully profitable, biotech company which was acquired by Genzyme Corporation in 2004. Prior to that he was the President and CEO and Director of Kyphon, Inc. a very successful orthopedic spine medical device company which was later acquired by Medtronic Corp. Prior to Kyphon Rick was the President, CEO and Director of CellPro Inc. one of the first publicly traded biotech companies to successfully develop products for stem cell transplantation. He has also held key management positions in a number of US and multinational healthcare companies including: Haemonetics Corporation, Baxter Healthcare-Fenwal Division, HemaScience Laboratories, where he was a founder (acquired by Baxter Healthcare), and Cytogen Corporation. His career began with a successful run in field sales and marketing at Ortho Diagnostics (a Johnson & Johnson Company). Mr. Murdock received his B.S. in Zoology from the University of California at Berkeley. He is an author of the book, “Patient Number One,” Crown Publishing, 2000.